Sobi Completes Significant Issuance of Class C Shares to Support Employee Programs
On August 31, 2026, the Swedish Orphan Biovitrum AB (commonly known as Sobi) announced the successful completion of a directed issue of redeemable and convertible Class C shares. This decision was originally approved during the company's Annual General Meeting (AGM) held on May 6, 2026, where the Board of Directors was authorized to facilitate the issuance as part of its strategy to secure obligations related to its long-term employee incentive program, affectionately called the All Employee Programme.
The necessity for this class C share issuance stemmed from Sobi's commitment to fulfilling its obligations under this program, which is designed to reward and incentivize its permanent employees. By ensuring the availability of resources through the issuance of these shares, Sobi is positioning itself to enhance employee engagement and retention, thereby bolstering its workforce's morale.
Following the AGM’s resolution, the Board of Directors acted swiftly, resolving on July 15, 2026, to repurchase all issued Class C shares, contingent upon receiving subscription and payment from Svenska Handelsbanken AB. Subsequently, Svenska Handelsbanken AB subscribed for all 223,677 issued Class C shares, culminating in the completion of this new share issue.
The financial aspect of this issuance was substantial; the total proceeds from this transaction amounted to SEK 122,732.80, a payment that was also processed on the same day of the announcement. The strategic intent behind the repurchase of these shares is clear—to secure Sobi’s obligations under the long-standing employee incentive program, demonstrating Sobi's dedication to employee welfare.
In a bid to create a more flexible equity structure, Sobi plans to convert the repurchased Class C shares into common stock as per the conversion provisions laid out in the company’s articles of association. By doing so, Sobi aims to ensure the future delivery of common shares to participants involved in the ongoing incentive program, thereby expanding their share in the company's success.
Currently, Sobi holds approximately 9,408,278 of its common shares and, following the repurchase, will see this figure increase to 9,631,955 common shares. This proactive move underscores the firm's commitment to employee support while simultaneously strengthening its financial and operational resilience.
Founded to unlock the potential of innovative biopharmaceuticals for individuals with rare diseases, Sobi has made significant strides since its inception. With a workforce of about 2,000 employees spread across Europe, North America, the Middle East, Asia, and Australia, the company reported revenue of SEK 28 billion in 2025. Sobi is publicly traded on the Nasdaq Stockholm with the ticker symbol STO: SOBI.
For more in-depth information about its innovative initiatives and operational updates, stakeholders can visit Sobi’s official website or follow the company on LinkedIn. Sobi continues to look ahead, striving to maintain and extend its mission to improve the lives of those dealing with rare diseases—empowering their employees is just one vital piece of this larger puzzle.
The necessity for this class C share issuance stemmed from Sobi's commitment to fulfilling its obligations under this program, which is designed to reward and incentivize its permanent employees. By ensuring the availability of resources through the issuance of these shares, Sobi is positioning itself to enhance employee engagement and retention, thereby bolstering its workforce's morale.
Following the AGM’s resolution, the Board of Directors acted swiftly, resolving on July 15, 2026, to repurchase all issued Class C shares, contingent upon receiving subscription and payment from Svenska Handelsbanken AB. Subsequently, Svenska Handelsbanken AB subscribed for all 223,677 issued Class C shares, culminating in the completion of this new share issue.
The financial aspect of this issuance was substantial; the total proceeds from this transaction amounted to SEK 122,732.80, a payment that was also processed on the same day of the announcement. The strategic intent behind the repurchase of these shares is clear—to secure Sobi’s obligations under the long-standing employee incentive program, demonstrating Sobi's dedication to employee welfare.
In a bid to create a more flexible equity structure, Sobi plans to convert the repurchased Class C shares into common stock as per the conversion provisions laid out in the company’s articles of association. By doing so, Sobi aims to ensure the future delivery of common shares to participants involved in the ongoing incentive program, thereby expanding their share in the company's success.
Currently, Sobi holds approximately 9,408,278 of its common shares and, following the repurchase, will see this figure increase to 9,631,955 common shares. This proactive move underscores the firm's commitment to employee support while simultaneously strengthening its financial and operational resilience.
Founded to unlock the potential of innovative biopharmaceuticals for individuals with rare diseases, Sobi has made significant strides since its inception. With a workforce of about 2,000 employees spread across Europe, North America, the Middle East, Asia, and Australia, the company reported revenue of SEK 28 billion in 2025. Sobi is publicly traded on the Nasdaq Stockholm with the ticker symbol STO: SOBI.
For more in-depth information about its innovative initiatives and operational updates, stakeholders can visit Sobi’s official website or follow the company on LinkedIn. Sobi continues to look ahead, striving to maintain and extend its mission to improve the lives of those dealing with rare diseases—empowering their employees is just one vital piece of this larger puzzle.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.